

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/698,121	10/30/2000		Jerome Aucouturier	746200-000062	5877
21967	7590 `	06/03/2002			
HUNTON 8			EXAMINER		
INTELLECT 1900 K STRE		OPERTY DEPART	EWOLDT, GERALD R		
SUITE 1200 WASHINGT	SUITE 1200 WASHINGTON, DC 20006-1109				PAPER NUMBER
	,			1644	12
				DATE MAILED: 06/03/2002	, –

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/698,121

Applicant(s)

Aucouturier et al.

Examiner

G.R. Ewoldt

Art Unit 1644



	The MAILING DATE of this communication appears	on the cover sh	eet with	the correspondence address				
	for Reply							
	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE	_3	_ MONTH(S) FROM				
	- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.							
- If the p - If NO p - Failure - Any re	greate or this communication. period for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply as to reply within the set or extended period for reply will, by statute, cause the pply received by the Office later than three months after the mailing date of the dipatent term adjustment. See 37 CFR 1.704(b).	and will expire SIX (6) he application to beco) MONTHS forme ABANDO	from the mailing date of this communication. ONED (35 U.S.C. § 133).				
Status								
1) 💢	Responsive to communication(s) filed on Mar 13, 2	<u>2002</u>		<u> </u>				
2a) 💢	This action is FINAL . 2b) ☐ This action							
3) 🗆	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.							
-	tion of Claims							
4) 🗶	Claim(s) <u>1-32</u>	* .		is/are pending in the application.				
	4a) Of the above, claim(s) <u>1-18 and 21-29</u>			is/are withdrawn from consideration.				
5) 🗆	Claim(s)			is/are allowed.				
6) 💢	Claim(s) 19, 20, and 30-32			is/are rejected.				
7) 🗌	Claim(s)							
8) 🗌	Claims	are	subject	to restriction and/or election requirement.				
Applica	ation Papers							
9) 🗌	The specification is objected to by the Examiner.							
10)	10)☐ The drawing(s) filed on is/are a)☐ accepted or b)☐ objected to by the Examiner.							
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11)	The proposed drawing correction filed on	is	: a)□ ε	approved b) \square disapproved by the Examiner.				
	If approved, corrected drawings are required in reply t	to this Office ac	etion.					
12)	The oath or declaration is objected to by the Exami	iner.						
Priority under 35 U.S.C. §§ 119 and 120								
13)💢	Acknowledgement is made of a claim for foreign pr	riority under 35	5 U.S.C.	§ 119(a)-(d) or (f).				
a) 🕽	a) ☑ All b) ☐ Some* c) ☐ None of:							
	1. 💢 Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
	3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).							
*S	ee the attached detailed Office action for a list of the							
14)	14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).							
_	a) The translation of the foreign language provisional application has been received.							
15) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
Attachm	• •	_						
	otice of References Cited (PTO-892)			0-413) Paper No(s)				
_	otice of Draftsperson's Patent Drawing Review (PTO-948) formation Disclosure Statement(s) (PTO-1449) Paper No(s).	_	ormal Pater	nt Application (PTO-152)				
31 🗀 IIII	offination Disclosure Statement(s) (PIO-1449) Paper No(s).	6) Uther:		l				

Serial No. 09/698,121 Art Unit 1644

DETAILED ACTION

- 1. Applicant's Reply and Remarks, filed 3/13/02, are acknowledged
- 2. Claims 19-20 and 30-32 are being acted upon.
- 3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 19-20 and 30-32 stand rejected under 35 U.S.C. 112, first paragraph, as based on a disclosure which is not enabling. Elements critical or essential to the practice of the invention, but not included in the claims are not enabled by the disclosure, for the reasons of record as set forth in Paper No. 10, mailed 12/13/01.

Applicant's arguments, filed 3/13/02, have been fully considered but they are not persuasive. Applicant argues that "The difference between Composition H and the other nine mannitan oleate compositions is the poly-ethoxylated derivative of mannitan oleate. As stated on page 7, lines 5-7, "As an example of [the composition of the present invention], there is the one in which the surfactant is an ethoxylated derivative of mannitan oleate having a number of EOs of between 5 and 15, preferably between 7 and 11." The term "EO" is utilized with its generally accepted definition as a unit of an ethoxylation indice. shown in the Table, Composition H has an ethoxylation indice of 8 It is the Examiner's position that the specification does not clearly disclose that "The difference between Composition H and the other nine mannitan oleate compositions is the polyethoxylated derivative of mannitan oleate," as asserted by Applicant, nor does the specification clearly disclose the specific formula of the claimed "poly-ethoxylated derivative." Further it is the Examiner's position that, contrary to Applicant's assertion, the term "EO" has "no generally accepted definition" in the immunological arts, i.e., the arts which pertain to adjuvants and vaccines.

Applicant further asserts that "HLB numbers (i.e., hydrophile-lipophile balance numbers)" are also "well known in the art." It is the Examiner's position that HLB numbers are not

well known in the immunological arts and Applicant's description of how said numbers are calculated in the instant Remarks is insufficient to provide an enabling specification. Applicant is advised that a proper amendment to the specification, including a proper declaration indicating that the amendment is derived from the European Pharmacopoeia and incorporates no new matter, would obviate this portion of the rejection.

- 5. No claim is allowed.
- 6. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (703) 308-9805 The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

G.R. Ewoldt, Ph.D.
Patent Examiner
Technology Center 1600
May 28, 2001

Patrick J. Nolan, Ph.D.

Primary Examiner

Pata Irolan

Technology Center 1600